ID   MOT8_HUMAN              Reviewed;         539 AA.
AC   P36021; Q7Z797;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   05-SEP-2006, sequence version 2.
DT   10-MAY-2017, entry version 138.
DE   RecName: Full=Monocarboxylate transporter 8;
DE            Short=MCT 8;
DE   AltName: Full=Monocarboxylate transporter 7;
DE            Short=MCT 7;
DE   AltName: Full=Solute carrier family 16 member 2;
DE   AltName: Full=X-linked PEST-containing transporter;
GN   Name=SLC16A2; Synonyms=MCT8, XPCT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=7981683; DOI=10.1093/hmg/3.7.1133;
RA   Lafreniere R.G., Carrel L., Willard H.F.;
RT   "A novel transmembrane transporter encoded by the XPCT gene in
RT   Xq13.2.";
RL   Hum. Mol. Genet. 3:1133-1140(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Kim D., Kanai Y., Choi H., Shin H., Kim J., Teraoka H., Shigeta Y.,
RA   Chairoungdua A., Babu E., Anzai N., Iribe Y., Endou H.;
RT   "X-linked PEST-containing transporter (XPCT) identified in the X-
RT   chromosome inactivation center is an acidic amino acid transporter
RT   which requires CD147 for its functional expression.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5]
RP   SUBUNIT.
RX   PubMed=19797118; DOI=10.1210/en.2009-0699;
RA   Visser W.E., Philp N.J., van Dijk T.B., Klootwijk W., Friesema E.C.,
RA   Jansen J., Beesley P.W., Ianculescu A.G., Visser T.J.;
RT   "Evidence for a homodimeric structure of human monocarboxylate
RT   transporter 8.";
RL   Endocrinology 150:5163-5170(2009).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [7]
RP   FUNCTION, AND MUTAGENESIS OF HIS-118; HIS-186 AND HIS-376.
RX   PubMed=23610131; DOI=10.1210/en.2012-2225;
RA   Groeneweg S., Lima de Souza E.C., Visser W.E., Peeters R.P.,
RA   Visser T.J.;
RT   "Importance of His192 in the human thyroid hormone transporter MCT8
RT   for substrate recognition.";
RL   Endocrinology 154:2525-2532(2013).
RN   [8]
RP   VARIANT MCT8 DEFICIENCY VAL-150.
RA   Friesema E., Grueters A., Halestrap A., Reeser M., Visser T.;
RT   "Mutations in a thyroid hormone transporter in patients with severe
RT   psychomotor retardation and high serum T3 levels.";
RL   Thyroid 13:672-672(2003).
RN   [9]
RP   VARIANT MCT8 DEFICIENCY PRO-438.
RX   PubMed=14661163; DOI=10.1086/380999;
RA   Dumitrescu A.M., Liao X.-H., Best T.B., Brockmann K., Refetoff S.;
RT   "A novel syndrome combining thyroid and neurological abnormalities is
RT   associated with mutations in a monocarboxylate transporter gene.";
RL   Am. J. Hum. Genet. 74:168-175(2004).
RN   [10]
RP   ERRATUM.
RA   Dumitrescu A.M., Liao X.-H., Best T.B., Brockmann K., Refetoff S.;
RL   Am. J. Hum. Genet. 74:598-598(2004).
RN   [11]
RP   IDENTIFICATION OF START CODON.
RX   PubMed=18398436; DOI=10.1038/ejhg.2008.66;
RA   Frints S.G., Lenzner S., Bauters M., Jensen L.R., Van Esch H.,
RA   des Portes V., Moog U., Macville M.V., van Roozendaal K.,
RA   Schrander-Stumpel C.T., Tzschach A., Marynen P., Fryns J.P., Hamel B.,
RA   van Bokhoven H., Chelly J., Beldjord C., Turner G., Gecz J.,
RA   Moraine C., Raynaud M., Ropers H.H., Froyen G., Kuss A.W.;
RT   "MCT8 mutation analysis and identification of the first female with
RT   Allan-Herndon-Dudley syndrome due to loss of MCT8 expression.";
RL   Eur. J. Hum. Genet. 16:1029-1037(2008).
RN   [12]
RP   VARIANTS MCT8 DEFICIENCY VAL-150 AND PRO-397.
RX   PubMed=15488219; DOI=10.1016/S0140-6736(04)17226-7;
RA   Friesema E.C.H., Grueters A., Biebermann H., Krude H., von Moers A.,
RA   Reeser M., Barrett T.G., Mancilla E.E., Svensson J., Kester M.H.A.,
RA   Kuiper G.G.J.M., Balkassmi S., Uitterlinden A.G., Koehrle J.,
RA   Rodien P., Halestrap A.P., Visser T.J.;
RT   "Association between mutations in a thyroid hormone transporter and
RT   severe X-linked psychomotor retardation.";
RL   Lancet 364:1435-1437(2004).
RN   [13]
RP   VARIANTS MCT8 DEFICIENCY PHE-120; PHE-156 DEL; MET-161; TRP-360 AND
RP   PRO-494.
RX   PubMed=15889350; DOI=10.1086/431313;
RA   Schwartz C.E., May M.M., Carpenter N.J., Rogers R.C., Martin J.,
RA   Bialer M.G., Ward J., Sanabria J., Marsa S., Lewis J.A., Echeverri R.,
RA   Lubs H.A., Voeller K., Simensen R.J., Stevenson R.E.;
RT   "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8
RT   (MCT8) gene.";
RL   Am. J. Hum. Genet. 77:41-53(2005).
RN   [14]
RP   VARIANTS MCT8 DEFICIENCY PHE-427 DEL AND ARG-490, AND POSSIBLE
RP   PATHOGENIC MECHANISM OF BRAIN DEVELOPMENT.
RX   PubMed=18636565; DOI=10.1002/humu.20808;
RA   Visser W.E., Jansen J., Friesema E.C.H., Kester M.H.A., Mancilla E.,
RA   Lundgren J., van der Knaap M.S., Lunsing R.J., Brouwer O.F.,
RA   Visser T.J.;
RT   "Novel pathogenic mechanism suggested by ex vivo analysis of MCT8
RT   (SLC16A2) mutations.";
RL   Hum. Mutat. 30:29-38(2009).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, VARIANTS MCT8 DEFICIENCY ARG-147;
RP   CYS-208; LEU-247; VAL-379; LEU-463 AND ASP-484, AND CHARACTERIZATION
RP   OF VARIANTS MCT8 DEFICIENCY ARG-147; CYS-208; LEU-247; VAL-379;
RP   LEU-463 AND ASP-484.
RX   PubMed=23550058; DOI=10.1210/me.2012-1356;
RA   Kersseboom S., Kremers G.J., Friesema E.C., Visser W.E., Klootwijk W.,
RA   Peeters R.P., Visser T.J.;
RT   "Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome
RT   affecting its cellular distribution.";
RL   Mol. Endocrinol. 27:801-813(2013).
RN   [16]
RP   INVOLVEMENT IN MCT8 DEFICIENCY, AND VARIANT MCT8 DEFICIENCY ARG-217.
RX   PubMed=25380603; DOI=10.1177/0883073814555189;
RA   La Piana R., Vanasse M., Brais B., Bernard G.;
RT   "Myelination delay and Allan-Herndon-Dudley syndrome caused by a novel
RT   mutation in the SLC16A2 gene.";
RL   J. Child Neurol. 30:1371-1374(2015).
RN   [17]
RP   FUNCTION, VARIANT MCT8 DEFICIENCY PHE-216, CHARACTERIZATION OF VARIANT
RP   MCT8 DEFICIENCY PHE-216, MUTAGENESIS OF SER-216, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=26426690; DOI=10.1371/journal.pone.0139343;
RA   Armour C.M., Kersseboom S., Yoon G., Visser T.J.;
RT   "Further insights into the Allan-Herndon-Dudley syndrome: clinical and
RT   functional characterization of a novel MCT8 mutation.";
RL   PLoS ONE 10:E0139343-E0139343(2015).
RN   [18]
RP   VARIANTS MCT8 DEFICIENCY THR-150; HIS-197; CYS-371 AND ASP-484,
RP   CHARACTERIZATION OF VARIANTS MCT8 DEFICIENCY PHE-120; THR-150;
RP   VAL-150; PHE-156 DEL; MET-161; HIS-197; TRP-360; CYS-371 PRO-397;
RP   PRO-438; ASP-484 AND PRO-494, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=25527620; DOI=10.1530/JME-14-0272;
RA   Fischer J., Kleinau G., Mueller A., Kuehnen P., Zwanziger D.,
RA   Kinne A., Rehders M., Moeller L.C., Fuehrer D., Grueters A., Krude H.,
RA   Brix K., Biebermann H.;
RT   "Modulation of monocarboxylate transporter 8 oligomerization by
RT   specific pathogenic mutations.";
RL   J. Mol. Endocrinol. 54:39-50(2015).
RN   [19]
RP   VARIANTS MCT8 DEFICIENCY HIS-197; ARG-490 AND GLU-490,
RP   CHARACTERIZATION OF VARIANTS MCT8 DEFICIENCY ARG-490 AND GLU-490, AND
RP   MUTAGENESIS OF GLY-490.
RX   PubMed=27805744; DOI=10.1002/humu.23140;
RA   Novara F., Groeneweg S., Freri E., Estienne M., Reho P.,
RA   Matricardi S., Castellotti B., Visser W.E., Zuffardi O., Visser T.J.;
RT   "Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in
RT   Three Families with the Allan-Herndon-Dudley Syndrome.";
RL   Hum. Mutat. 38:260-264(2017).
CC   -!- FUNCTION: Very active and specific thyroid hormone transporter.
CC       Stimulates cellular uptake of thyroxine (T4), triiodothyronine
CC       (T3), reverse triiodothyronine (rT3) and diidothyronine. Does not
CC       transport Leu, Phe, Trp or Tyr. {ECO:0000269|PubMed:23550058,
CC       ECO:0000269|PubMed:26426690}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:19797118,
CC       ECO:0000269|PubMed:25527620}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23550058,
CC       ECO:0000269|PubMed:25527620, ECO:0000269|PubMed:26426690}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:23550058,
CC       ECO:0000269|PubMed:25527620}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver and heart.
CC       {ECO:0000269|PubMed:7981683}.
CC   -!- DISEASE: Monocarboxylate transporter 8 deficiency (MCT8
CC       deficiency) [MIM:300523]: Consists of a severe form of X-linked
CC       psychomotor retardation combined with abnormal thyroid hormone
CC       (TH) levels. Thyroid hormone deficiency can be caused by defects
CC       of hormone synthesis and action, but it has also been linked to a
CC       defect in cellular hormone transport. Affected patients are males
CC       with abnormal relative concentrations of three circulating
CC       iodothyronines, as well as severe neurological abnormalities,
CC       including global developmental delay, central hypotonia, spastic
CC       quadriplegia, dystonic movements, rotary nystagmus, and impaired
CC       gaze and hearing. Heterozygous females had a milder thyroid
CC       phenotype and no neurological defects.
CC       {ECO:0000269|PubMed:14661163, ECO:0000269|PubMed:15488219,
CC       ECO:0000269|PubMed:15889350, ECO:0000269|PubMed:18636565,
CC       ECO:0000269|PubMed:23550058, ECO:0000269|PubMed:25380603,
CC       ECO:0000269|PubMed:25527620, ECO:0000269|PubMed:26426690,
CC       ECO:0000269|PubMed:27805744, ECO:0000269|Ref.8}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Abnormal brain development associated with MCT8
CC       deficiency may be the consequence of either decreased or increased
CC       intracellular T3 concentrations. {ECO:0000269|PubMed:18636565}.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC       Monocarboxylate porter (TC 2.A.1.13) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB60374.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAB60375.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U05321; AAB60375.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; U05316; AAB60375.1; JOINED; Genomic_DNA.
DR   EMBL; U05317; AAB60375.1; JOINED; Genomic_DNA.
DR   EMBL; U05318; AAB60375.1; JOINED; Genomic_DNA.
DR   EMBL; U05319; AAB60375.1; JOINED; Genomic_DNA.
DR   EMBL; U05320; AAB60375.1; JOINED; Genomic_DNA.
DR   EMBL; U05315; AAB60374.1; ALT_INIT; mRNA.
DR   EMBL; AB085789; BAC76827.1; -; mRNA.
DR   EMBL; AC004073; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL157934; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS14426.2; -.
DR   PIR; I39295; I39295.
DR   RefSeq; NP_006508.2; NM_006517.4.
DR   UniGene; Hs.75317; -.
DR   ProteinModelPortal; P36021; -.
DR   BioGrid; 112455; 4.
DR   STRING; 9606.ENSP00000276033; -.
DR   DrugBank; DB00149; L-Leucine.
DR   DrugBank; DB00150; L-Tryptophan.
DR   DrugBank; DB00135; L-Tyrosine.
DR   DrugBank; DB00451; Levothyroxine.
DR   DrugBank; DB01583; Liotrix.
DR   DrugBank; DB00119; Pyruvic acid.
DR   TCDB; 2.A.1.13.10; the major facilitator superfamily (mfs).
DR   iPTMnet; P36021; -.
DR   PhosphoSitePlus; P36021; -.
DR   BioMuta; SLC16A2; -.
DR   DMDM; 114152841; -.
DR   EPD; P36021; -.
DR   MaxQB; P36021; -.
DR   PaxDb; P36021; -.
DR   PeptideAtlas; P36021; -.
DR   PRIDE; P36021; -.
DR   Ensembl; ENST00000587091; ENSP00000465734; ENSG00000147100.
DR   GeneID; 6567; -.
DR   KEGG; hsa:6567; -.
DR   UCSC; uc031tjy.2; human.
DR   CTD; 6567; -.
DR   DisGeNET; 6567; -.
DR   GeneCards; SLC16A2; -.
DR   GeneReviews; SLC16A2; -.
DR   H-InvDB; HIX0056105; -.
DR   HGNC; HGNC:10923; SLC16A2.
DR   HPA; HPA072719; -.
DR   MalaCards; SLC16A2; -.
DR   MIM; 300095; gene.
DR   MIM; 300523; phenotype.
DR   neXtProt; NX_P36021; -.
DR   OpenTargets; ENSG00000147100; -.
DR   Orphanet; 59; Allan-Herndon-Dudley syndrome.
DR   PharmGKB; PA35814; -.
DR   eggNOG; ENOG410IMVZ; Eukaryota.
DR   eggNOG; ENOG410Z4JM; LUCA.
DR   GeneTree; ENSGT00740000115479; -.
DR   HOVERGEN; HBG006387; -.
DR   InParanoid; P36021; -.
DR   KO; K08231; -.
DR   OMA; IKQTWVL; -.
DR   OrthoDB; EOG091G0449; -.
DR   PhylomeDB; P36021; -.
DR   TreeFam; TF313792; -.
DR   Reactome; R-HSA-879518; Transport of organic anions.
DR   ChiTaRS; SLC16A2; human.
DR   GeneWiki; SLC16A2; -.
DR   GenomeRNAi; 6567; -.
DR   PRO; PR:P36021; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147100; -.
DR   CleanEx; HS_SLC16A2; -.
DR   ExpressionAtlas; P36021; baseline and differential.
DR   Genevisible; P36021; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0008028; F:monocarboxylic acid transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0015293; F:symporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0015349; F:thyroid hormone transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0015718; P:monocarboxylic acid transport; TAS:ProtInc.
DR   GO; GO:0043252; P:sodium-independent organic anion transport; TAS:Reactome.
DR   GO; GO:0070327; P:thyroid hormone transport; IMP:UniProtKB.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR030761; MCT8.
DR   InterPro; IPR011701; MFS.
DR   InterPro; IPR020846; MFS_dom.
DR   PANTHER; PTHR11360:SF207; PTHR11360:SF207; 1.
DR   Pfam; PF07690; MFS_1; 1.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Cell membrane; Complete proteome; Disease mutation;
KW   Membrane; Polymorphism; Reference proteome; Symport; Transmembrane;
KW   Transmembrane helix; Transport.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    539       Monocarboxylate transporter 8.
FT                                /FTId=PRO_0000211401.
FT   TOPO_DOM      2     96       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     97    117       Helical. {ECO:0000255}.
FT   TOPO_DOM    118    143       Extracellular. {ECO:0000255}.
FT   TRANSMEM    144    164       Helical. {ECO:0000255}.
FT   TOPO_DOM    165    171       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    172    192       Helical. {ECO:0000255}.
FT   TOPO_DOM    193    200       Extracellular. {ECO:0000255}.
FT   TRANSMEM    201    221       Helical. {ECO:0000255}.
FT   TOPO_DOM    222    229       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    230    250       Helical. {ECO:0000255}.
FT   TOPO_DOM    251    258       Extracellular. {ECO:0000255}.
FT   TRANSMEM    259    279       Helical. {ECO:0000255}.
FT   TOPO_DOM    280    322       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    323    343       Helical. {ECO:0000255}.
FT   TOPO_DOM    344    356       Extracellular. {ECO:0000255}.
FT   TRANSMEM    357    377       Helical. {ECO:0000255}.
FT   TOPO_DOM    378    386       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    387    407       Helical. {ECO:0000255}.
FT   TOPO_DOM    408    409       Extracellular. {ECO:0000255}.
FT   TRANSMEM    410    430       Helical. {ECO:0000255}.
FT   TOPO_DOM    431    447       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    448    468       Helical. {ECO:0000255}.
FT   TOPO_DOM    469    477       Extracellular. {ECO:0000255}.
FT   TRANSMEM    478    498       Helical. {ECO:0000255}.
FT   TOPO_DOM    499    539       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   VARIANT     120    120       S -> F (in MCT8 deficiency; impaired
FT                                homodimerization; dbSNP:rs113994162).
FT                                {ECO:0000269|PubMed:15889350,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_059054.
FT   VARIANT     147    147       G -> R (in MCT8 deficiency; impaired
FT                                thyroid hormone transporter activity;
FT                                does not affect localization to the cell
FT                                membrane). {ECO:0000269|PubMed:23550058}.
FT                                /FTId=VAR_074572.
FT   VARIANT     150    150       A -> T (in MCT8 deficiency; impaired
FT                                homodimerization; dbSNP:rs373279555).
FT                                {ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_074573.
FT   VARIANT     150    150       A -> V (in MCT8 deficiency; does not
FT                                affect homodimerization activity;
FT                                dbSNP:rs104894936).
FT                                {ECO:0000269|PubMed:15488219,
FT                                ECO:0000269|PubMed:25527620,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_022348.
FT   VARIANT     156    156       Missing (in MCT8 deficiency; increased
FT                                homodimerization activity).
FT                                {ECO:0000269|PubMed:15889350,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_059055.
FT   VARIANT     161    161       V -> M (in MCT8 deficiency; increased
FT                                homodimerization activity).
FT                                {ECO:0000269|PubMed:15889350,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_059056.
FT   VARIANT     197    197       R -> H (in MCT8 deficiency; does not
FT                                affect homodimerization activity;
FT                                dbSNP:rs727504155).
FT                                {ECO:0000269|PubMed:25527620,
FT                                ECO:0000269|PubMed:27805744}.
FT                                /FTId=VAR_074574.
FT   VARIANT     208    208       G -> C (in MCT8 deficiency; impaired
FT                                thyroid hormone transporter activity;
FT                                impaired localization to the cell
FT                                membrane). {ECO:0000269|PubMed:23550058}.
FT                                /FTId=VAR_074575.
FT   VARIANT     216    216       S -> F (in MCT8 deficiency; decreased
FT                                thyroid hormone transport; decreased
FT                                protein abundance; no effect on
FT                                localization to the plasma membrane;
FT                                dbSNP:rs398124232).
FT                                {ECO:0000269|PubMed:26426690}.
FT                                /FTId=VAR_075145.
FT   VARIANT     217    217       L -> R (in MCT8 deficiency; atypical
FT                                form; characterized by developmental
FT                                delay hypotonia and delayed myelination).
FT                                {ECO:0000269|PubMed:25380603}.
FT                                /FTId=VAR_078497.
FT   VARIANT     247    247       P -> L (in MCT8 deficiency; impaired
FT                                thyroid hormone transporter activity;
FT                                does not affect localization to the cell
FT                                membrane). {ECO:0000269|PubMed:23550058}.
FT                                /FTId=VAR_074576.
FT   VARIANT     323    323       I -> L (in dbSNP:rs12849411).
FT                                /FTId=VAR_057723.
FT   VARIANT     360    360       L -> W (in MCT8 deficiency; impaired
FT                                homodimerization; dbSNP:rs104894939).
FT                                {ECO:0000269|PubMed:15889350,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_059057.
FT   VARIANT     371    371       R -> C (in MCT8 deficiency; impaired
FT                                homodimerization; dbSNP:rs587784384).
FT                                {ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_074577.
FT   VARIANT     379    379       D -> V (in MCT8 deficiency; impaired
FT                                thyroid hormone transporter activity;
FT                                does not affect localization to the cell
FT                                membrane). {ECO:0000269|PubMed:23550058}.
FT                                /FTId=VAR_074578.
FT   VARIANT     397    397       L -> P (in MCT8 deficiency; does not
FT                                affect homodimerization activity;
FT                                dbSNP:rs122455132).
FT                                {ECO:0000269|PubMed:15488219,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_022349.
FT   VARIANT     427    427       Missing (in MCT8 deficiency).
FT                                {ECO:0000269|PubMed:18636565}.
FT                                /FTId=VAR_059058.
FT   VARIANT     438    438       L -> P (in MCT8 deficiency; does not
FT                                affect homodimerization activity;
FT                                dbSNP:rs104894931).
FT                                {ECO:0000269|PubMed:14661163,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_022350.
FT   VARIANT     463    463       P -> L (in MCT8 deficiency; impaired
FT                                thyroid hormone transporter activity;
FT                                does not affect localization to the cell
FT                                membrane). {ECO:0000269|PubMed:23550058}.
FT                                /FTId=VAR_074579.
FT   VARIANT     484    484       G -> D (in MCT8 deficiency; does not
FT                                affect homodimerization activity;
FT                                impaired thyroid hormone transporter
FT                                activity; impaired localization to the
FT                                cell membrane).
FT                                {ECO:0000269|PubMed:23550058,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_074580.
FT   VARIANT     490    490       G -> E (in MCT8 deficiency; results in a
FT                                mild clinical phenotype; retains some
FT                                residual thyroid hormone transporter
FT                                activity). {ECO:0000269|PubMed:27805744}.
FT                                /FTId=VAR_078498.
FT   VARIANT     490    490       G -> R (in MCT8 deficiency; impaired
FT                                thyroid hormone transporter activity;
FT                                dbSNP:rs794727799).
FT                                {ECO:0000269|PubMed:18636565,
FT                                ECO:0000269|PubMed:27805744}.
FT                                /FTId=VAR_059059.
FT   VARIANT     494    494       L -> P (in MCT8 deficiency; does not
FT                                affect homodimerization activity;
FT                                dbSNP:rs104894938).
FT                                {ECO:0000269|PubMed:15889350,
FT                                ECO:0000269|PubMed:25527620}.
FT                                /FTId=VAR_059060.
FT   MUTAGEN     118    118       H->A: Reduction of thyroid hormone (TH)
FT                                transport. {ECO:0000269|PubMed:23610131}.
FT   MUTAGEN     186    186       H->A: No effect on thyroid hormone (TH)
FT                                transport. {ECO:0000269|PubMed:23610131}.
FT   MUTAGEN     216    216       S->A: No effect on thyroid hormone
FT                                transport. No effect on protein
FT                                abundance. No effect on protein
FT                                localization to the plasma membrane.
FT                                {ECO:0000269|PubMed:26426690}.
FT   MUTAGEN     376    376       H->A: No effect on thyroid hormone (TH)
FT                                transport. {ECO:0000269|PubMed:23610131}.
FT   MUTAGEN     490    490       G->A: No effect on thyroid hormone (TH)
FT                                transport. {ECO:0000269|PubMed:27805744}.
SQ   SEQUENCE   539 AA;  59511 MW;  E4DB873D59FA4DD6 CRC64;
     MALQSQASEE AKGPWQEADQ EQQEPVGSPE PESEPEPEPE PEPVPVPPPE PQPEPQPLPD
     PAPLPELEFE SERVHEPEPT PTVETRGTAR GFQPPEGGFG WVVVFAATWC NGSIFGIHNS
     VGILYSMLLE EEKEKNRQVE FQAAWVGALA MGMIFFCSPI VSIFTDRLGC RITATAGAAV
     AFIGLHTSSF TSSLSLRYFT YGILFGCGCS FAFQPSLVIL GHYFQRRLGL ANGVVSAGSS
     IFSMSFPFLI RMLGDKIKLA QTFQVLSTFM FVLMLLSLTY RPLLPSSQDT PSKRGVRTLH
     QRFLAQLRKY FNMRVFRQRT YRIWAFGIAA AALGYFVPYV HLMKYVEEEF SEIKETWVLL
     VCIGATSGLG RLVSGHISDS IPGLKKIYLQ VLSFLLLGLM SMMIPLCRDF GGLIVVCLFL
     GLCDGFFITI MAPIAFELVG PMQASQAIGY LLGMMALPMI AGPPIAGLLR NCFGDYHVAF
     YFAGVPPIIG AVILFFVPLM HQRMFKKEQR DSSKDKMLAP DPDPNGELLP GSPNPEEPI
//
